1062P - Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckM...

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Immunotherapy
Therapy
Presenter Hans Hammers
Citation Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378
Authors H. Hammers1, E.R. Plimack2, J.R. Infante3, B.I. Rini4, D. McDermott5, L. Lewis6, M.H. Voss7, P. Sharma8, S.K. Pal9, A. Razak10, C.K. Kollmannsberger11, D. Heng12, J. Spratlin13, B. McHenry14, P. Gagnier15, A. Amin16
  • 1Oncology, Kimmel Cancer Center at Johns Hopkins, 21287 - Baltimore/US
  • 2Department Of Hematology/oncology, Fox Chase Cancer Center, PA 19111-2497 - Philadelphia/US
  • 3Drug Development Program, Sarah Cannon Research Institute, Nashville/US
  • 4Department Of Hematology And Oncology, Cleveland Clinic Taussig Cancer Institute, 44195 - Cleveland/US
  • 5Division Of Hematology/oncology, Beth Israel Deaconess Med. Center, 02215 - Boston/US
  • 6Pharmacology & Toxicology, Dartmouth-Hitchcock Medical Center, Lebanon/US
  • 7Medical Oncology, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 8Department Of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston/US
  • 9Medical Oncology And Experimental Therapuetics, City of Hope, 91010 - Duarte/US
  • 10Medical Oncology, Princess Margaret Cancer Centre, Toronto/CA
  • 11Department Of Medical Oncology, BCCA Vancouver Cancer Centre, V5Z4E6 - Vancouver, BC/CA
  • 12Medical Oncology, Tom Baker Cancer Centre, T2N 4N2 - Calgary/CA
  • 13Medical Oncology, University of Alberta Cross Cancer Institute, Edmonton/CA
  • 14Biostatistics, Bristol-Myers Squibb, Princeton/US
  • 15Oncology, Bristol-Myers Squibb, Princeton/US
  • 16Medical Oncology, Levine Cancer Institute, Charlotte/US

Abstract

Background

Nivo is an anti-PD1 antibody that has shown improved overall survival (OS) vs everolimus in previously treated mRCC (N Engl J Med 2015;373:1803–13). Ipi is a CTLA 4 antibody, approved for advanced melanoma. CheckMate 016 showed acceptable safety and tolerability, enhanced antitumor activity, and encouraging OS results for the nivo + ipi combination in patients (pts) with mRCC (NCT01472081); here we report updated results.

Methods

Pts with mRCC were randomized to intravenous (IV) nivo 3 mg/kg + ipi 1 mg/kg (nivo3 + ipi1), nivo 1 mg/kg + ipi 3 mg/kg (nivo1 + ipi3), or nivo 3 mg/kg + ipi 3 mg/kg (nivo3 + ipi3) every 3 weeks for 4 doses, followed by nivo3 IV every 2 weeks until progression or toxicity. Key endpoints included safety, objective response rate (ORR), duration of response (DOR), OS, and progression-free survival (PFS).

Results

Both the nivo3 + ipi1 and nivo1 + ipi3 arms enrolled 47 pts, with median follow-up of 22 (range, 1–34) months (nivo3 + ipi3 arm [n = 6] discontinued due to toxicity). Baseline pt characteristics were generally balanced between the arms. Prior systemic therapy was administered in 47% and 55% in nivo3 + ipi1 and nivo1 + ipi3 arms, respectively. Grade 3–4 treatment-related adverse events (TRAEs) were reported in 38% (nivo3 + ipi1) and 62% (nivo1 + ipi3) of patients; of these, the most common were ↑ lipase (15% vs 28%), ↑ ALT (4% vs 21%), diarrhea (4% vs 15%), ↑ AST (4% vs 13%), and colitis (0% vs 15%). The most common grade 3–4 select TRAEs were gastrointestinal (4% vs 23%) and hepatic (6% vs 21%). Efficacy is summarized in the table.

Conclusions

Almost 2 years of follow-up of patients with mRCC treated with nivo + ipi shows manageable safety as observed previously, high ORR and durable responses with promising OS. Ipi showed dose-related toxicity, which further supports development of nivo3 + ipi1 in the first-line setting.

Nivo3 + ipi1 Nivo1 + ipi3
n = 47 n = 47
ORR, n (%) 19 (40) 19 (40)
Median DOR, mos (range) 20.4 (2.1–32.2+) 19.7 (2.8 + –31.7+)
Stable disease, n (%) 19 (40) 17 (36)
Progressive disease, n (%) 8 (17) 8 (17)
Median OS, mos (range) Not reached (3.5–34.5+) 32.6 (1.1–34.3+)
Median PFS, mos (range) 6.6 (1.1 + –33.7+) 9.1 (1.0–33.1+)
+= censored

Clinical trial identification

NCT01472081

Legal entity responsible for the study

Bristol-Myers Squibb

Funding

Bristol-Myers Squibb

Disclosure

H. Hammers: Consulting/Advisory: BMS, Exelixis, Pfizer, Cerulean Research Funding: SFJ, BMS, Exelixis, Newlink, Pfizer, GSK, Tracon. E.R. Plimack: Consulting/Advisory: Merck, Dendreon, Novartis, BMS, Pfizer, GSK, Acceleron Pharma, Genentech/Roche Research Funding: Merck, BMS, GSK, Acceleron Pharma, Dendreon, Lilly, AZ Patents: U.S. Patent No.: 14/588.503 Filed 1/2/2015. B.I. Rini: Consulting/Advisory: Pfizer, Novartis, Acceleron Research Funding: Pfizer, BMS, Peleton Travel: Pfizer. D. McDermott: Consulting/Advisory: BMS, Merck, Genentech, Novartis, Pfizer, Eisai, Exelixis Research Funding: Prometheus Labs. M.H. Voss: Honoraria: Novartis Consulting/Advisory: Novartis, GSK, Exelixis, Natera, Calithera Research Funding: BMS Travel/Accomodations: Takeda, Novartis. P. Sharma: compensation/leadership role and stock with Kite, Jounce, Evelo, and Neon. Consultant role with GSK. Amgen, BMS, and AZ. Own patient licensed to Jounce and patients licensed to BMS, Jounce Merck. Research as principal investigator for BMS, GSK, and AZ. S.K. Pal: Honoraria from Novartis, Medivation and Astellas Pharma Receives consulting fees from Pfizer, Novartis, Aveo, Genentech, Exelixis, BMS, Astellas and GSK. C.K. Kollmannsberger: Honoraria: Pfizer, Novartis, BMS, Participated in national or international advisory boards for Pfizer, Novartis, BMS, Sanofi, Astellas, Lilly. D. Heng: My conflicts are consultant/advisory role to BMS Pfizer Novartis. J. Spratlin: Honoraria: Lilly and Celgene Consulting/Advisory: Lilly and Celgene Research Funding: Celgene and Sanofi and Roche. B. McHenry: Employment: BMS Stock: BMS Research: BMS. P. Gagnier: Employment: BMS Stock: BMS Research: BMS Travel: BMS. A. Amin: Consulting/Advisory: BMS, Merck Speakers' Bureau: BMS, Merck, Pfizer Research Funding: BMS, Merck, Prometheus, Argos. All other authors have declared no conflicts of interest.